Meyer Colin John's Form 4 filing
Reata Pharmaceuticals Inc (RETA) · filed Mar 6, 2023
- Accession no.
- 0001209191-23-016380
- Filed
- Mar 6, 2023
- Trade date
- Mar 2-3, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 3 derivative transactions. Open-market sales total $8.15M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Meyer Colin JohnCIK 0001662392 | Officer (Chief Innovation Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | Class A common stock | CConversionAcquired | +88,636 | – | – | 179,149 | Direct | |
| Mar 2, 2023 | Class A common stock | SSaleDisposed | −22,752 | $85.23 | −$1,939,152.96 | 156,397 | Direct | |
| Mar 2, 2023 | Class A common stock | SSaleDisposed | −34,794 | $86.49 | −$3,009,333.06 | 121,603 | Direct | |
| Mar 2, 2023 | Class A common stock | SSaleDisposed | −19,099 | $87.55 | −$1,672,117.45 | 102,504 | Direct | |
| Mar 2, 2023 | Class A common stock | SSaleDisposed | −11,181 | $88.50 | −$989,518.5 | 91,323 | Direct | |
| Mar 2, 2023 | Class A common stock | SSaleDisposed | −810 | $90.58 | −$73,369.8 | 90,513 | Direct | |
| Mar 3, 2023 | Class A common stock | SSaleDisposed | −5,286 | $87.35 | −$461,732.1 | 85,227 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | Class B common stock | MOption exerciseDisposed | −88,636 | $0.00 | $0 | 0 | Direct | |
| Mar 2, 2023 | Class A common stock | MOption exerciseAcquired | +88,636 | $11.00 | +$974,996 | 162,940 | Direct | |
| Mar 2, 2023 | Class A common stock | CConversionDisposed | −88,636 | – | – | 74,304 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.